University of California, San Francisco
San Francisco, California, 94158, United States
NCT Number: NCT07096245
This study is testing different ways of sharing a short, community-informed video about flu and COVID-19 vaccines to see how people respond to it. The video was created with input from Indigenous community members in California and provides information to support vaccine decision-making. Participants may see the video in one of three ways: through a paid advertisement on social media, from a trusted community organization, or from someone they know personally. After watching the video, viewers will be asked to answer one question about how much they trust it, and they may choose to complete a short survey about their vaccine views and how they received the video. The goal is to understand how trust in vaccine information changes depending on who shares it, and to improve the way health messages are delivered to Indigenous and other underserved communities.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
San Francisco, California, 94158, United States
This is a randomized dissemination trial evaluating the impact of different message delivery strategies on trust, attitudes, and behavioral intentions related to flu and COVID-19 vaccination. The intervention consists of a short (approximately 2-minute) culturally tailored video, developed using human-centered design and community-based participatory approaches with Indigenous communities in California.
Participants are exposed to the video through one of three dissemination arms: (1) paid advertisements on Facebook and Instagram targeting adults 65 and older in California; (2) peer-to-peer sharing by "seed" participants recruited from a prior phase of the study; and (3) community-based organization (CBO) outreach using established communication channels. All participants view the same video.
After viewing the video, participants are asked to respond to a single poll item ("How much do you trust this video?") and are invited to complete an optional, anonymous online survey assessing vaccine confidence, trust in the information source, and willingness to share the video. Survey responses are linked to the dissemination arm for comparative analysis.
Seed participants receive personalized, trackable video links and instructions to share them with at least 10 contacts in their network. Click-level analytics (e.g., timestamp, referral source, general location) are collected through Bitly or Rebrandly links. YouTube analytics will also be used to evaluate video engagement (e.g., views, retention, traffic source). No identifiable health information is collected unless participants voluntarily provide contact information to complete the survey by phone.
The primary outcome is the level of trust in the video across dissemination arms. Secondary outcomes include survey completion rate, willingness to share the video, and changes in vaccine-related attitudes. Data will be stratified by dissemination method and, for seed participants, linked to prior social network data collected in Phase 1.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The intervention is a brief, community-informed educational video (2-3 minutes) focused on seasonal flu and COVID-19 vaccination. The video was developed using human-centered design and community-based participatory methods with Indigenous community members in California. It aims to promote trust in vaccines by presenting clear, culturally relevant health information.
The video is disseminated using three behavioral delivery strategies: (1) paid advertisements on Facebook and Instagram targeting adults in California, (2) peer-to-peer sharing by participants who previously enrolled in the study and are invited to serve as "seeds" who share the video with their personal contacts, and (3) distribution by trusted community-based organizations (CBOs) using their existing communication networks, including WhatsApp, social media, email, and newsletters. All viewers are prompted to complete a one-question trust poll and invited to participate in an optional anonymous survey on vaccine attitud
Time frame: immediately after exposure
Participants will be asked to answer a single poll question after viewing a 2-3 minute vaccine education video: "How much do you trust this video?" Responses will be collected on a 4-point Likert scale (Not at all, A little, Mostly, Completely). The primary outcome is the level of trust reported, compared across dissemination arms (paid social media ads, peer-to-peer sharing, and community-based organization distribution). Analysis will assess differences in trust levels based on who shared the video.
Time frame: Immediately after video exposure
Assesses participants' reported likelihood of getting a seasonal flu or COVID-19 vaccine after viewing the intervention video. Measured on a 6-point scale from "Very unlikely" to "Very likely," including an option for participants who have already received the vaccine. Analysis will examine variation by dissemination arm and correlation with trust in the video.
Time frame: Immediately after video exposure
Participants are asked whether the video provided them with new information related to flu or COVID-19 vaccines. This binary outcome (Yes/No/Not sure) helps assess the video's educational value.
Time frame: Immediately after video exposure
Assesses how much participants trust the person or group from whom they received the video. Measured on a 4-point scale (Not at all, A little, Mostly, Completely).
University of California, San Francisco
Other
Acronym: Conectados
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03587610
Vaccination
Le Mans, France
View Trial DetailsNCT01054053
Vaccination
Neufchâtel-en-Bray, France
View Trial DetailsNCT07007377
Flu, Flu-like Symptoms
São Paulo, Brazil
View Trial DetailsNCT04936776
Hematologic Diseases, Hemic and Lymphatic Diseases
New York, United States
View Trial Details